📰 Full Story
OpenAI on April 16-17, 2026 unveiled GPT‑Rosalind, a domain‑specific artificial intelligence model tailored for life sciences research and early‑stage drug discovery.
Named for Rosalind Franklin, the model is designed to support evidence synthesis, hypothesis generation, experimental planning and multi‑step scientific workflows across biochemistry, genomics, protein engineering and translational medicine.
OpenAI said GPT‑Rosalind is available as a research preview inside ChatGPT, Codex and the API but access is restricted to a vetted trusted‑access programme for qualified enterprise customers.
The company is also releasing a free Life Sciences research plugin for Codex that links models to more than 50 scientific tools and databases.
Launch partners and collaborators include Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute, Los Alamos National Laboratory and Dyno Therapeutics.
OpenAI published benchmark results showing a 0.751 pass rate on BixBench and outperformance of GPT‑5.4 on several LABBench2 tasks; a partner evaluation on unpublished RNA sequences reportedly placed model outputs above the 95th percentile of human experts on certain prediction tasks.
OpenAI said technical and governance safeguards will be used to limit misuse and that the preview is aimed at organisations working to improve human health outcomes.







💬 Commentary